FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to neurology, clinical laboratory diagnostics, and can be used for diagnostics of Parkinson's disease with dementia. Peripheral blood is sampled, the CD45+ cell fraction is recovered and the recovered cell fraction is lysed. Concentration of total protein of alpha-synuclein is measured in CD45+ cell lysate by enzyme immunoassay. If the total alpha-synuclein concentration is more than or equal to 1.90 ng/mcg of total protein, Parkinson's disease with dementia is diagnosed.
EFFECT: method enables diagnosing Parkinson's disease with dementia, reducing the cost of the study and simplifying the study by isolating a homogeneous fraction of CD45+ cells from the patient's blood by magnetic sorting and measuring the concentration of total alpha-synuclein in the CD45+ cell lysate.
1 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSTICS OF PARKINSON'S DISEASE | 2017 |
|
RU2657763C1 |
| METHOD FOR DIAGNOSING PARKINSON'S DISEASE ASSOCIATED WITH MUTATIONS IN GLUCOCEREBROSIDASE (GBA) GENE | 2020 |
|
RU2750357C1 |
| PROTOFIBRIL-BINDING ANTIBODIES AND USE THEREOF IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, DEMENTIA WITH LEWY BODIES AND OTHER ALPHA-SYNUCLEINOPATHIES | 2011 |
|
RU2555526C2 |
| ALPHA-SYNUCLEIN MODULATORS | 2018 |
|
RU2797677C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE AND DIFFUSE LEWY BODY DISEASE | 2024 |
|
RU2835349C1 |
| PEPTIDE IMMUNOGENS FROM C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND COMPOSITIONS BASED ON THEM FOR TREATMENT OF SYNUCLEONOPATHIES | 2018 |
|
RU2810774C2 |
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| ALLOSTERIC PHARMACOLOGICAL CHAPERONE THAT RESTORES FUNCTION OF GLUCOCEREBROSIDASE | 2023 |
|
RU2809824C1 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND OPTIONS OF THEIR USE | 2019 |
|
RU2812765C2 |
| METHOD FOR AUTOANTIGEN VACCINATION IN A HUMAN PATIENT | 2016 |
|
RU2734924C2 |
